Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28253440 | 0.81 | EPHX1 (0.41) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL4172800 | 0.78 | EPHX1 (0.47) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL712857 | 0.76 | EPHX1 (0.50) | MEN1KMT2AEPHX1 | |
| SCHEMBL28434695 | 0.76 | CA2 (0.39) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL28224073 | 0.75 | EPHX1 (0.53) | MEN1KMT2AEPHX1 | |
| SCHEMBL8779996 | 0.72 | — | — | |
| SCHEMBL28438866 | 0.71 | CA2 (0.39) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL3134199 | 0.70 | CA2 (0.42) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL1526166 | 0.70 | — | — | |
| SCHEMBL11498478 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394948-B2 | Reagents utilizing a serinol scaffold for labeling synthetic oligonucleotides | GLEN RESEARCH CORPORATION (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110077389-A1 | Novel Reagents Utilizing A Serinol Scaffold For Labeling Synthetic Oligonucleotides | Nelson Biotechnologies, Inc. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077389-A1 | Novel Reagents Utilizing A Serinol Scaffold For Labeling Synthetic Oligonucleotides | PCNA, POLL, DNMT3L | CA2 3079/4885ALDH1A1 4756/4885POLB 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.